(24/7 MARKET NEWS) – Elevation Oncology, Inc. (NASDAQ: ELEV) stated that it will deliver an oral presentation covering preclinical proof-of-concept data for EO-3021 at the New Drugs on the Horizon special session at the American Association for Cancer Research (AACR) Annual Meeting 2023, April 14-19, 2023 in Orlando, Florida.
Elevation Oncology is trading at $1.75, up $0.32 (+22.38%), on 160 thousand shares traded.
Its 52-week trading range is $0.7229 to 4.6099. It’s now trading at price levels last seen in June and, although it may not do it today, if it can maintain this strong trading volume, its setup is favorable to potentially reverse June’s move to $2+.
24/7 MARKET NEWS, INC Disclaimer
24/7 MARKET NEWS (“24/7 MN”) is dedicated to covering various underreported segments of the stock markets. Our goal is to help you to better understand these markets, but 24/7 MN is neither an investment advisor nor a financial advisor, and no information provided here is to be interpreted as a suggestion to buy or sell stocks or other investment products. All opinions, news, research, analysis, prices or other information contained on 247marketnews.com, its press releases, or other services are provided for educational purposes only and do not constitute investment advice. You are solely responsible for the investment decisions you make.
Please go to www.247marketnews.com or https://www.247marketnews.com/terms-disclaimer/ for further information.
